FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a compound of formula (I), where R1-R9, R5', R6', W, X, Y, Z, n, m are defined in the claims, the invention has a neuroprotective effect. Also the following is disclosed: a method of its preparation, a pharmaceutical composition containing it, and the use of the compound for the preparation of a medicinal product for the prevention and/or treatment of diseases or disorders associated with neuronal damage.
(I)
EFFECT: obtaining a compound with neuroprotector action.
7 cl, 1 tbl, 48 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS OF 2-AMINOPYRIMIDINE AND THEIR USE | 2020 |
|
RU2795914C1 |
| p-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR, METHOD FOR ITS PRODUCTION AND MEDICAL USE | 2019 |
|
RU2762562C1 |
| TETRAHYDROISOQUINOLINE COMPOUND AS A POTASSIUM CHANNELS MODULATOR, ITS PREPARATION AND APPLICATION | 2021 |
|
RU2800873C1 |
| HETEROCYCLIC AMIDE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PREPARATION AND USE THEREOF | 2020 |
|
RU2823875C1 |
| HETEROCYCLIC COMPOUND, INTERMEDIATE COMPOUND, A METHOD OF ITS PRODUCTION AND ITS USE | 2019 |
|
RU2800153C2 |
| DERIVATIVES OF BENZIMIDAZOLIDINONE AS AGENTS FOR MUSCARINIC RECEPTORS | 2002 |
|
RU2288919C2 |
| PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | 2021 |
|
RU2819346C1 |
| SUBSTITUTED BENZENE COMPOUNDS | 2013 |
|
RU2658919C2 |
| TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | 2021 |
|
RU2815022C1 |
| PDE9 INHIBITOR AND ITS USE | 2018 |
|
RU2793732C2 |
